Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Licenses OncoMethylome Biomarkers

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences has licensed exclusive, worldwide rights from OncoMethylome Sciences to DNA methylation biomarkers for use in the stool-based detection of colorectal cancer.

In addition, Madison, Wis.-based Exact Sciences also licensed non-exclusive access to part of OncoMethylome's platform technology. In return, the Belgian firm will receive milestone payments and royalties on net sales

Exact Sciences' primary product, which is currently in development, is a stool-based DNA test for colorectal cancer screening. The agreement with OncoMethylome follows last year's licensing of worldwide rights to Hologic's Invader plus and real-time Invader detection chemistries for colorectal screening applications.

"Our team has developed a new approach to stool-DNA testing that uniquely includes multiple methylation markers in a single assay, and achieves exceptionally high sensitivity and specificity," Exact Sciences President and CEO Kevin Conroy said in a statement. "The inclusion of these markers makes us even more confident about the likelihood of success with our upcoming validation study."

He added that the firm intends to discuss the results of that study on Oct. 29, at the American Association of Cancer Research meeting in Philadelphia.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.